Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA's Total Debt to $75 Million, a 29% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company's key product, ASCENIV, is expected to drive significant revenue growth and improve margins, supported by a completed pediatric trial and upcoming sBLA submission. Past legal controversies about an auditor's resignation caused temporary investor ...
ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level. The post Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge appeared first on Investor's Business Daily.
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ:ADMA) on behalf of ADMA Biologics stockholders. Our investigation concerns whether ADMA Biologics has violated the federal securities laws and/or engaged in other u...
NEW YORK--(BUSINESS WIRE)---- $ADMA #CLASSACTIONLAWSUIT--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ: ADMA). The investigation concerns whether ADMA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn mo...
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Skyler Bloom – Senior Director, Business Development & Corporate Strategy Adam Grossman – President and Chief Executive Officer Brad Tade – Chief Financial Officer and Treasurer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Anthony Petrone – Mizuho Group Gary N...
NEW YORK--(BUSINESS WIRE)---- $ADMA #INVESTIGATION--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ: ADMA). The investigation concerns whether ADMA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more ab...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.